GleamWall
中文EN

VNOV VitaNova Life Sciences Corp

Wholesale-Apparel, Piece Goods & Notions · OTC · SEC CIK 1699709 · Fiscal year ends 04/30

Financial factors as of 2026-07-31 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY22.0%
TTM net income YoY-113.3%
TTM EPS YoY—
Revenue 3-yr CAGR420.5%
Net income 3-yr CAGR—

Margins

Gross margin26.9%
Operating margin-2.7%
Net margin-3.5%
FCF margin—
EBITDA margin—

Returns

ROE-6.0%
ROA-5.1%
ROIC (approx.)-11.9%
Asset turnover1.45x

Leverage & solvency

Liabilities / assets13.9%
Debt / equity0.00x
Current ratio7.13x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-4.89x
Accruals ratio-30.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-04-30FY20252025-04-30
Income statement
Revenue$3.03M$2.66M
Cost of revenue$2.11M$1.09M
Gross profit$910,589$1.58M
SG&A expense$733,795$158,122
Operating income$3,601$1.21M
Interest expense$0$4,506
Pretax income$6,581$1.20M
Income tax$43,885$353,558
Net income-$37,304$850,746
EPS (basic)-0.000.10
EPS (diluted)—0.03
Weighted avg. shares (diluted)—25.01M
Balance sheet
Cash & equivalents$1.60M$782,810
Receivables$726,743$1.27M
Inventory$105,613$44,247
Current assets$2.43M$2.26M
Total assets$2.45M$2.26M
Current liabilities$395,781$347,567
Total liabilities$395,781$347,567
Shareholders' equity$2.05M$1.91M
Shares outstanding8.34M8.34M
Cash flow statement
Operating cash flow$814,407$192,774
Financing cash flow$0-$3,000
Stock-based compensation$179,400$2,000

Free plan shows the latest 2 periods; Pro shows all 10 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.